Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Solid Tumor : recurrent or refractory solid tumors (including rhabdoid and malignant germ cell tumors of the CNS) and leukemias
This is a phase II study to determine the response rate of MLN8237 drug in children with relapsed (cancer that has come back) or refractory (cancer that continues to grow) cancers. Children and young adults with recurrent or relapsed cancers (solid tumors and leukemias) for which there is no known effective therapy will be eligible. The study drug is taken by mouth once a day for 7 days every 21 days. You can continue to get treatment on this study for up to 2 years, as long as your cancer does not get worse, and you are not having serious side effects from the study drug. After treatment, you will have routine follow-up exams and medical tests. Medical information will be collected for 5 years after entering the study.
Cynthia Wetmore, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Phone: 901-595-2544 or 901-595-4599
Tabatha E. Doyle, RN
Coordinator, Brain Tumor Program
For the current eligibility status of this clinical study, patient’s family, relatives and/or referring physicians may contact St. Jude Children’s Research Hospital at (901) 595-4599 or (901) 595-2544.
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.